Abstract
In the present 6-week double-blind, randomised, multicentre study, the atypical neuroleptic remoxipride was compared to haloperidol in acute schizophrenic patients (DSM-III). Seventy-one patients entered the study, 36 in the remoxipride group and 35 in the haloperidol group. There were ten early withdrawals, four in the remoxipride group and six patients in the haloperidol group. The Present State Examination (PSE) profile revealed a similar reduction in the symptom clusters of psychosis in both treatment groups. Forty-seven per cent of the patients in the remoxipride group and 34% of the patients in the haloperidol group showed clinically relevant improvement (reduction of BPRS total score ≥ 50%). All extrapyramidal symptoms except “glabella tap” occurred significantly less frequently in the remoxipride group as compared to the haloperidol group. Substantially lower incidences of EPS were found by active questioning in the remoxipride group compared to the haloperidol group. In addition, considerably lower incidences were observed in the remoxipride group with respect to drowsiness/somnolence, tiredness/fatigue and concentrating difficulty. At the end of treatment 66% of the patients in the haloperidol group and 22% in the remoxipride group were using anticholinergics. No consistent changes were found in the mean plasma HVA level in either treatment group. In responders (reduction of BPRS total score ≥ 50%) lower baseline HVA levels were observed in both treatment groups. This study indicates that the newly developed neuroleptic remoxipride is an effective antipsychotic compound, which is clinically safe and well tolerated. In particular, few EPS were induced by remoxipride, as compared to haloperidol.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreasen NC (1981) Scale for the assessment of negative symptoms (SANS). Iowa City: The University of Iowa
Bowers MB Jr, Swigar ME, Jatlow, PI, Hoffman F, Giocoechea N (1986) Early neuroleptic response in psychotic men and women: Correlation with plasma HVA and MHPG. Compr Psychiatry 27:181
Chang WH, Chen TY, Lee CF, Hung JC, Hu WH, Yeh EK (1988) Plasma homovanillic acid levels and subtyping of schizophrenia. Psychiatr Res 23:239–244
Chouinard G, Turnier L (1986) An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. Psychopharmacol Bull 22:267–271
Davidson M, Davis KL (1988) A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry 45:561–563
Davila R, Manero E, Zumarraga M, Andia, I, Schweitzer JW, Friedhoff AJ (1988) Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45:564–567
Davis KL, Davidson M, Mohs RC et al. (1985) Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science 227:1601–1602
Den Boer JA, Verhoeven WMA, Westenberg HGM (1987) Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia. Psychopharmacol Bull 23:206–210
DSM-III (1980) Diagnostic and statistical manual of mental disorder. The American Psychiatric Association
Guy W (1976) ECDEU assessment manual for psychopharmacology. Red ed. National Institute of Mental Health, Rockville, MD, pp 217–222
Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987) Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 44:604–607
Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ (1988) Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatr Res 25:233–242
Köhler C, Ögren SO, Fuxe K (1984) Studies on the mechanism of action of substituted benzamide drugs. Acta Psychiatr Scand [Suppl] 311:125–137
Lapierre YD, Nair NPV, Chouinard G, et al. (1989) A controlled dose-ranging study of remoxipride vs. haloperidol in schizophrenia — a Canadian multicentre trial. In: International Symposium: Development of a new antipsychotic: Remoxipride. Monaco, June 19–20 p 10
Laursen LA, Gerlach J (1986) Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta Psychiatr Scand 73:17–21
Lindström L (1985) Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatr Res 14:265–273
Lindström L, Besev G, Stening G, Widerlöv E (1985) An open study of remoxipride, a benzamide derivative, in schizophrenia. Psychopharmacology 86:241–243
Magnusson O, Fowler CJ, Köhler C, Ögren SO (1986) Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology 25:187–197
McCreadie RG, Morrison D, Eccleston D, Gall RG, Loudon J, Mitchell MJ (1985) An open multicentre study of the treatment of florid schizophrenia with remoxipride. Acta Psychiatr Scand 72:139–143
McCreadie RG, Todd N, Livingstone M, Eccleston D, Watt JAG, Tait D, Crocket G, Mitchell MG, Huitfeldt B (1988) A double blind comparative study of remoxipride and thioridazine in acute phase of schizophrenia. Acta Psychiatr Scand 78:49–56
Ögren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Ängeby K, Florvall L (1983) remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459–474
Ögren SO, Hall H, Köhler C, Magnusson O (1988) Neurophramacological properties of remoxipride. Pharmacopsychiatry 21:65
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Overall JE, Gorham DR (1976) BPRS: Brief Psychiatric Rating Scale. In: Guy W (ed) ECDEU assessment manual for psychopharmacology. Red. ed. Rockville, MD National Institute of Mental Health, pp 157–169
Pickar D, Labarea R, Linnoila M et al. (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 224:954–956
Pickard D, Labarea R, Doran AR, Wolkovitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43:669
Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand [Suppl 212] 45:11–19
Wing JK, Cooper JE, Sartorius N (1979) The measurement and classification of psychiatric symptoms. Cambridge University Press, London
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Den Boer, J.A., Ravelli, D.P., Huisman, J. et al. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology 102, 76–84 (1990). https://doi.org/10.1007/BF02245748
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245748